Contact
searchSearch
HMP Global

Advertisement

Advertisement

ADVERTISEMENT

FDA Alerts

Alopecia Areata, blad head
FDA Alerts
Deuruxolitinib FDA Approved for Severe Alopecia Areata in Adults
07/30/2024
The FDA has approved deuruxolitinib (LEQSELVI) 8 mg tablets for the treatment of adults with severe alopecia areata, a condition affecting approximately 300,000 individuals in the United States.
The FDA has approved deuruxolitinib (LEQSELVI) 8 mg tablets for the treatment of adults with severe alopecia areata, a condition affecting approximately 300,000 individuals in the United States.
The FDA has approved...
07/30/2024
The Dermatologist
Atopic dermatitis
FDA Alerts
FDA Approves Roflumilast Cream 0.15% for Treatment of Atopic Dermatitis in Adults and Children Aged 6 and Older
07/09/2024
The US Food and Drug Administration has approved roflumilast cream 0.15% for the treatment of mild to moderate atopic dermatitis in adults and children aged 6 and older.
The US Food and Drug Administration has approved roflumilast cream 0.15% for the treatment of mild to moderate atopic dermatitis in adults and children aged 6 and older.
The US Food and Drug...
07/09/2024
The Dermatologist
AD
FDA Alerts
FDA Approves Tralokinumab Autoinjector for Adults with Moderate-to-Severe Atopic Dermatitis
06/15/2024
Riya Gandhi, MA, Associate Editor
The US Food and Drug Administration has approved a new Adbry (tralokinumab-ldrm) 300 mg single-dose autoinjector, offering a new administration option for adult patients with moderate-to-severe atopic dermatitis.
The US Food and Drug Administration has approved a new Adbry (tralokinumab-ldrm) 300 mg single-dose autoinjector, offering a new administration option for adult patients with moderate-to-severe atopic dermatitis.
The US Food and Drug...
06/15/2024
The Dermatologist
Actinic Keratosis
FDA Alerts
FDA Approves Almirall’s Klisyri for Expanded Treatment Area of Actinic Keratosis
06/11/2024
Riya Gandhi, MA, Associate Editor
The US Food and Drug Administration (FDA) has recently approved an expansion for the use of Klisyri (tirbanibulin) to treat actinic keratosis (AK) on larger areas of the face or scalp, up to 100 cm².
The US Food and Drug Administration (FDA) has recently approved an expansion for the use of Klisyri (tirbanibulin) to treat actinic keratosis (AK) on larger areas of the face or scalp, up to 100 cm².
The US Food and Drug...
06/11/2024
The Dermatologist
Atopic Derm
FDA Alerts
Dupixent Receives Expanded FDA Approval for Atopic Dermatitis with Moderate to Severe Hand and Foot Involvement
01/19/2024
Riya Gandhi, MA, Associate Editor
The US FDA has approved an update to the label for Dupixent (dupilumab) for atopic dermatitis for patients ages 12 years and older with AD and uncontrolled moderate to severe involvement of the hands and/or feet.
The US FDA has approved an update to the label for Dupixent (dupilumab) for atopic dermatitis for patients ages 12 years and older with AD and uncontrolled moderate to severe involvement of the hands and/or feet.
The US FDA has approved an...
01/19/2024
The Dermatologist
atopic dermatitis
FDA Alerts
Tralokinumab-ldrm Approved for Treatment of Moderate to Severe Atopic Dermatitis in Pediatric Patients
12/18/2023
Jessica Garlewicz, Digital Managing Editor
The US Food and Drug Administration recently announced approval of tralokinumab-ldrm (Adbry) to include pediatric patients aged 12 to 17 years with moderate to severe atopic dermatitis.
The US Food and Drug Administration recently announced approval of tralokinumab-ldrm (Adbry) to include pediatric patients aged 12 to 17 years with moderate to severe atopic dermatitis.
The US Food and Drug...
12/18/2023
The Dermatologist
Roflumilast Topical Foam
FDA Alerts
Roflumilast Topical Foam, 0.3% Approved for Treatment of Seborrheic Dermatitis
12/18/2023
Jessica Garlewicz, Digital Managing Editor
As the first drug approved for seborrheic dermatitis with a new mechanism of action in over 2 decades, roflumilast foam, 0.3% is indicated for treatment of seborrheic dermatitis in adult and pediatric patients.
As the first drug approved for seborrheic dermatitis with a new mechanism of action in over 2 decades, roflumilast foam, 0.3% is indicated for treatment of seborrheic dermatitis in adult and pediatric patients.
As the first drug approved for...
12/18/2023
The Dermatologist
FDA Alerts
Secukinumab Approved as New Biologic Treatment Option for Hidradenitis Suppurativa
11/01/2023
Jessica Garlewicz, Digital Managing Editor
The US Food and Drug Administration recently announced approval of Cosentyx (secukinumab) for the treatment of hidradenitis suppurativa.
The US Food and Drug Administration recently announced approval of Cosentyx (secukinumab) for the treatment of hidradenitis suppurativa.
The US Food and Drug...
11/01/2023
The Dermatologist
psoriasis
FDA Alerts
Bimekizumab-bkzx Approved for Adults With Moderate to Severe Plaque Psoriasis
10/19/2023
Jessica Garlewicz, Digital Managing Editor
The US Food and Drug Administration recently announced approval of bimekizumab-bkzx for the treatment of adults with moderate to severe plaque psoriasis.
The US Food and Drug Administration recently announced approval of bimekizumab-bkzx for the treatment of adults with moderate to severe plaque psoriasis.
The US Food and Drug...
10/19/2023
The Dermatologist
FDA Alerts
Nivolumab Approved as Adjuvant Treatment for Patients With Completely Resected Stage IIB or Stage IIC Melanoma
10/19/2023
Jessica Garlewicz, Digital Managing Editor
The US Food and Drug Administration recently announced approval of nivolumab as an adjuvant treatment for eligible patients with stage IIB or IIC completely resected melanoma.
The US Food and Drug Administration recently announced approval of nivolumab as an adjuvant treatment for eligible patients with stage IIB or IIC completely resected melanoma.
The US Food and Drug...
10/19/2023
The Dermatologist

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Current Issue

August 2024
Volume 32
Issue 5
Current Issue
Issue Archive

Advertisement

Advertisement

Advertisement

Advertisement

Popular Articles

Derm Dx
What Is This Growth on the Leg?
08/23/2016
Hannah Liu, MD
Usha Alapati, MD
and Amor Khachemoune, MD, FAAD, FACMS
A 53-year-old otherwise healthy man was referred to us by his primary care provider for the evaluation of a large, asymptomatic, polypoid mass over his left lateral leg that he had for more than 25 years.
A 53-year-old otherwise healthy man was referred to us by his primary care provider for the evaluation of a large, asymptomatic, polypoid mass over his left lateral leg that he had for more than 25 years.
A 53-year-old otherwise healthy...
08/23/2016
The Dermatologist
DNA to Host Virtual Psoriasis Symposium
10/30/2012
The Dermatology Nurses' Association (DNA) announced that it will host its first virtual symposium on Saturday, November 10, 2012. The virtual symposium, which will focus on psoriasis, will offer a unique educational format for dermatology and...
The Dermatology Nurses' Association (DNA) announced that it will host its first virtual symposium on Saturday, November 10, 2012. The virtual symposium, which will focus on psoriasis, will offer a unique educational format for dermatology and...
The Dermatology Nurses'...
10/30/2012
The Dermatologist
FDA Clears Non-Invasive Fat Destruction Device
07/18/2016
The FDA has approved the non-invasive fat destruction device, UltraShape Power (Syneron Candela) for the non-invasive reduction of abdominal circumference via fat cell destruction.
The FDA has approved the non-invasive fat destruction device, UltraShape Power (Syneron Candela) for the non-invasive reduction of abdominal circumference via fat cell destruction.
The FDA has approved the...
07/18/2016
The Dermatologist
New Dermatology Marketing Program to Provide Social Media Management
07/17/2012
Maximize Social Media, LLC, a social media management firm with offices in Florida and California, has announced a new dermatology marketing program.The firm will provide dermatologists with management of the top social media platforms,...
Maximize Social Media, LLC, a social media management firm with offices in Florida and California, has announced a new dermatology marketing program.The firm will provide dermatologists with management of the top social media platforms,...
Maximize Social Media, LLC, a...
07/17/2012
The Dermatologist
News
Q. Can you name four common co-morbidities of psoriasis?
06/02/2016
Click here to see the answer. 
Click here to see the answer. 
Click here to see the...
06/02/2016
The Dermatologist

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Subscribe

The Dermatologist Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Latest Quizzes and Trivia

Quiz
QUIZ: Topical PDE-4 Inhibitors For Atopic Dermatitis, Seborrheic Dermatitis, and Psoriasis
08/10/2024
What strategies did Dr Merola emphasize for atopic dermatitis?
What strategies did Dr Merola emphasize for atopic dermatitis?
What strategies did Dr Merola...
08/10/2024
The Dermatologist
contact dermtitis + Neck + Eczema + rash
Quiz
QUIZ: Patient Experiences in Contact Dermatitis and Patch Testing
07/14/2024
What is a common challenge for patients during the patch testing week?
What is a common challenge for patients during the patch testing week?
What is a common challenge for...
07/14/2024
The Dermatologist
gloves hands
Quiz
Quiz: Barrier to Mental Health Support in Patients with Atopic Dermatitis
05/30/2024
Riya Gandhi, MA, Associate Editor
According to a recent interview with Jessica Johnson, MPH, what is a significant barrier to seeking mental health support among patients with atopic dermatitis?
According to a recent interview with Jessica Johnson, MPH, what is a significant barrier to seeking mental health support among patients with atopic dermatitis?
According to a recent interview...
05/30/2024
The Dermatologist
Atopic dermatitis
Quiz
Quiz: Atopic Dermatitis Spotlight
05/06/2024
Riya Gandhi, MA, Associate Editor
Which class of medications received a "general thumbs up" in the latest guidelines for atopic dermatitis management due to their efficacy and low cancer risk?
Which class of medications received a "general thumbs up" in the latest guidelines for atopic dermatitis management due to their efficacy and low cancer risk?
Which class of medications...
05/06/2024
The Dermatologist
basal cell carcinoma
Quiz
True or False: Basal Cell Carcinoma on Vermilion Lip
05/01/2024
Is basal cell carcinoma on the vermilion lip a distinctly rare phenomenon, sparsely documented in existing literature?
Is basal cell carcinoma on the vermilion lip a distinctly rare phenomenon, sparsely documented in existing literature?
Is basal cell carcinoma on the...
05/01/2024
The Dermatologist
Atopic Dermatitis + Eczema + Itch + Rash + Kids + Legs + Elbow + Knee
Quiz
Quiz: Navigating New Therapies in Atopic Dermatitis
04/10/2024
Riya Gandhi, MA, Associate Editor
In a recent interview, Dr Jonathan Silverberg, mentioned the importance of understanding the strengths and weaknesses of new therapies. Which aspect did he particularly emphasize as crucial in clinical practice?
In a recent interview, Dr Jonathan Silverberg, mentioned the importance of understanding the strengths and weaknesses of new therapies. Which aspect did he particularly emphasize as crucial in clinical practice?
In a recent interview, Dr...
04/10/2024
The Dermatologist
AD
Quiz
Trivia: Atopic Dermatitis Patients With Alopecia Areata
02/28/2024
Riya Gandhi, MA, Associate Editor
02/28/2024
The Dermatologist
AD
Quiz
Trivia: Itch Cycle and OTC Products
12/27/2023
12/27/2023
The Dermatologist
psoriasis
Quiz
Trivia: Recommended Treatment For Psoriasis
12/20/2023
Jessica Garlewicz, Digital Managing Editor
When treating mild to moderate and moderate to severe plaque psoriasis, what is the recommended treatment?
When treating mild to moderate and moderate to severe plaque psoriasis, what is the recommended treatment?
When treating mild to moderate...
12/20/2023
The Dermatologist
Ilka Arun Netravali, MD, PhD, FAAD
Quiz
Dupilumab Mechanism of Action
11/07/2023
Jessica Garlewicz, Digital Managing Editor
According to a recent interview with Dr Ilka Arun Netravali, what is the mechanism of action behind dupilumab that translates to effective suppression of atopic disease?
According to a recent interview with Dr Ilka Arun Netravali, what is the mechanism of action behind dupilumab that translates to effective suppression of atopic disease?
According to a recent interview...
11/07/2023
The Dermatologist

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement